enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Traditional Chinese medicine - Wikipedia

   en.wikipedia.org/wiki/Traditional_Chinese_medicine

   Some TCM textbooks still recommend preparations containing animal tissues, but there has been little research to justify the claimed clinical efficacy of many TCM animal products. [ 142 ] Some compounds can include the parts of endangered species, including tiger bones [ 143 ] and rhinoceros horn [ 144 ] which is used for many ailments (though ...

3. List of traditional Chinese medicines - Wikipedia

   en.wikipedia.org/wiki/List_of_traditional...

   Pinellia ternata is believed under TCM to be the strongest of all TCM herbs for removing phlegm. [citation needed] Active ingredients of this herb include: methionine, glycine, β-aminobutyric acid, γ-aminobutyric acid, ephedrine, trigonelline, phytosterols and glucoronic acid. [50] Care should be taken as crow dipper is toxic. [72]

4. Karuna Therapeutics' Schizophrenia Drug Could Be a ... - AOL

   www.aol.com/karuna-therapeutics-schizophrenia...

   If Karuna is successful, its drug would offer relief to a large patient population. According to the World Health Organization, schizophrenia affects approximately 24 million people, or one in 300 ...

5. Chinese herbology - Wikipedia

   en.wikipedia.org/wiki/Chinese_herbology

   Chinese herbology (traditional Chinese: 中藥學; simplified Chinese: 中药学; pinyin: zhōngyào xué) is the theory of traditional Chinese herbal therapy, which accounts for the majority of treatments in traditional Chinese medicine (TCM).

6. Bristol Myers Squibb acquires Karuna Therapeutics for $14 ...

   www.aol.com/news/bristol-myers-squibb-acquires...

   Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna's stock on Thursday.

7. Bristol Myers to buy schizophrenia drugmaker Karuna ...

   www.aol.com/news/bristol-myers-buy-schizophrenia...

   Karuna's drug is expected to be patent-protected in the United States through the mid-2030s. The deal is expected to hit Bristol Myers' earnings per share by roughly 30 cents in 2024 due to the ...